Search Within

Howard Scher

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Journal Article (79)
  2. Meeting Abstract (58)
  3. Review (2)
  4. Conference Paper (1)
Groups
  1. Department of Medicine (140)
  2. Genitourinary Oncology Service (140)
  3. Molecular Imaging and Therapy Service (140)
  4. Solid Tumor Oncology Division (140)
  5. Radiology, Department of (129)
  6. GSK Faculty (125)

More Groups

People
  1. Steven Larson (110)
  2. Michael Morris (95)
  3. Susan Slovin (34)
  4. Neeta Pandit-Taskar (32)
  5. Josef Fox (28)
  6. Daniel Danila (26)

More People

Years
  1. 2025 (2)
  2. 2024 (4)
  3. 2023 (1)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (48)
  2. Clinical Cancer Research (18)
  3. Journal of Nuclear Medicine (18)
  4. Annals of Oncology (3)
  5. Cancer (3)
  6. Cancer Research (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (50)
  2. American Association for Cancer Research (23)
  3. Society of Nuclear Medicine (18)
  4. Springer (8)
  5. Elsevier Science, Inc. (7)
  6. Elsevier Inc. (5)

More Publishers

Results (140)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I trial of docetaxel and pulse-dose 17-allylamino-17- demethoxygeldanamycin in adult patients with solid tumors
    Journal Article

    Iyer, G.; Morris, M. J.; Rathkopf, D.; Slovin, S. F.; Steers, M.; Larson, S. M.; Schwartz, L. H.; Curley, T.; Delacruz, A.; Ye, Q.; more...
    Cancer Chemotherapy and Pharmacology (2012)

    Fulltext@MSK | Save
  • Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Journal Article

    Dennis, E. R.; Jia, X.; Mezheritskiy, I. S.; Stephenson, R. D.; Schoder, H.; Fox, J. J.; Heller, G.; Scher, H. I.; Larson, S. M.; Morris, M. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castration-resistant prostate cancer (mCRPC): Results of a phase I pilot study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Borwick, L. S.; Momen, L.; Curley, T.; Arauz, G.; Larson, S. M.; Fleisher, M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Slovin, S. F.; Morris, M. J.; Steinbrecher, J. E.; Chen, Y.; Fleisher, M.; Larson, S. M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Initial study of bone scan tumor area for early surrogate outcome assessment in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Kim, H. J.; Brown, M. S.; Chu, G. H.; Gjertson, D. W.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Morris, M. J.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload
    Meeting Abstract

    Dennis, E. R.; Fox, J. J.; Larson, S. M.; Farrelly, J. S.; Schwartz, L. H.; Schòˆder, H.; Haupt, E. C.; Borwick, L. S.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Initial analytic validation of automated bone scan measures for treatment response assessment in patients with metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Chu, G. H.; Brown, M. S.; Kim, H. J.; Auerbach, M.; Poon, C.; Ramakrishna, B.; Vidovic, A.; Gjertson, D. W.; Morris, M. J.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Automated tumor detection on bone scans for treatment response assessment
    Meeting Abstract

    Brown, M. S.; Chu, G. H.; Kim, H. J.; Auerbach, M.; Poon, C.; Vidovic, A.; Ramakrishna, B.; Gjertson, D. W.; Morris, M. J.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC)
    Meeting Abstract

    Baklajian, A.; Dennis, E. R.; Buddle, J. R.; Fox, J. J.; Schoder, H.; Morris, M. J.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload
    Meeting Abstract

    Morris, M. J.; Farrelly, J. S.; Fox, J. J.; Dennis, E. R.; Schwartz, L. H.; Schoder, H.; Haupt, E. C.; Borwick, L. S.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save